COMMUNIQUÉS West-GlobeNewswire
-
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
06/07/2026 -
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
06/07/2026 -
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
06/07/2026 -
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
06/07/2026 -
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
06/07/2026 -
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
06/07/2026 -
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
06/07/2026 -
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
06/07/2026 -
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
06/07/2026 -
Canada Diagnostic Centres, a Novacap Portfolio Company, Announces Acquisition of Shift Imaging
06/07/2026 -
ThreeSixty Journalism Kicks Off Multimedia Storytelling Institute Summer Program for Local High School Students
06/07/2026 -
Catheter Precision, Inc. Announces Issuance of Two Key Patents
06/07/2026 -
La recommandation du CMUH fait passer le TECVAYLI®▼ (teclistamab) de Johnson & Johnson, associé au daratumumab, au rang de traitement conventionnel potentiel pour le myélome multiple récidivant ou réfractaire
06/07/2026 -
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
06/07/2026 -
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
06/07/2026 -
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
06/07/2026 -
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
06/07/2026 -
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
06/07/2026 -
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
06/07/2026
Pages